Calliditas Therapeutics AB (publ)
CALT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $6,956,328 | $4,690,123 | $5,687,440 | $6,199,129 |
| - Cash | $973,733 | $1,249,094 | $955,507 | $996,304 |
| + Debt | $979,133 | $728,822 | $213,216 | $4,786 |
| Enterprise Value | $6,961,728 | $4,169,851 | $4,945,149 | $5,207,611 |
| Revenue | $1,206,888 | $802,879 | $229,347 | $874 |
| % Growth | 50.3% | 250.1% | 26,141.1% | – |
| Gross Profit | $1,129,831 | $787,678 | $229,347 | $874 |
| % Margin | 93.6% | 98.1% | 100% | 100% |
| EBITDA | -$367,803 | -$388,817 | -$471,832 | -$379,398 |
| % Margin | -30.5% | -48.4% | -205.7% | -43,409.4% |
| Net Income | -$466,185 | -$412,268 | -$509,537 | -$436,511 |
| % Margin | -38.6% | -51.3% | -222.2% | -49,944.1% |
| EPS Diluted | -17.38 | -15.56 | -20.04 | -19.46 |
| % Growth | -11.7% | 22.4% | -3% | – |
| Operating Cash Flow | -$434,655 | -$311,354 | -$461,588 | -$309,181 |
| Capital Expenditures | -$12,787 | -$2,512 | -$22,654 | $0 |
| Free Cash Flow | -$447,442 | -$313,866 | -$484,242 | -$309,181 |